The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
According to a Biotech manager in a radio 4 interview a day or two (6AM) and never repeated during the day as far as I am aware said, over the past 20 years very few companies had reached the main market and that Aim was no longer doing the job for which it was intended due to the main markets lack of interest. Another factor was lack of awareness which is certainly true for AGL - I did not see nor heard nor read any mention of AGLs FDA approval in the media. I presume companies do issue a press release when they have some really good news so how are investors to invest when they do not know of its existance.
Will we get results of above in the next few weeks as predicted and if they are best in class what good is it going to be to Angle if we do not apply for FDA approval?
Same old story - rinse and repeat, rinse and repeat. Getting close to where I will throw my hand in.
Oh yes there is- some i have dabbled in or watched are ukog ,see, solg, and many others - remember this is AIM we are talking about. I bought into this one during covid when i was bored and regretted it the very next day and every day since !
"A good product will self itself" now needs to include the words "unless there is a better product.
I was going to say .... Since FDA approval there has been nothing new apart (from the ovarian trial). No wonder the SP is where it is.
Does anyone know what the programme is for this year? - do the BoD know? Over the past year we have had mentions of head, neck and prostrate cancers. Are we likely to submit a request for fda clearance re ovarian cancer? Do we expect uk clearance for breast cancer in the near future? Since FD
Just thought I'd throw in to the mix that founders of a company get a tax break when setting up a company - which is fair enough in my opinion.
It appears from share chat that there are still 48 PIs still invested.
Understood that NEDs are discouraged from holding shares in a company where they are a NED, thus retaining some degree of impartiality from the executive. Angle is a good 2 years behind where it should be mainly due to occurrences beyond their control. Survival this year depends on contracts and more contracts rather than medical news. Happy and healthy New Year to all.
Agree phantom - and lets not forget to take the US medical insurance companies out to lunch as soon as we get accreditation!
May be down to lack of accreditation???
There is one message to learn from this share and that there is no dead certainty in share dealing!!!! The broker's £2+ looks like pie in the sky in the short term and possibly even the mid term. Meantime there is a lot going on in the oncology world - a new drug which doubles the time it takes for breast cancer to spread and shrunk the tumour in 23% of cases. ( Yes phantom I realise it does not impinge on Parsortix). Angle may or may not come good but its a long road ahead judging by the present rate of progress and that is where the risk lies.
would anyone wish to buy a company which maybe will take another 2 years to make a reasonable profit? Cancer research is moving apace.
Exact sciences corp in US received FDA approval for a liquid biopsy test for colorectal cancer with an efficacy of 95% in 2014. The corp's share price over 20 odd years is also quite revealing - doubled after approval, then lost 75%, then through acquisitions and tie in with the Mayo clinic went from $5 to $155 and has lately been sliding, now at $41.
director buys did nothing for me and, I suspect many others who are losing confidence. Typical aim stunt!
A.N. STATED A COUPLE OF YEARS AGO THAT THEY WOULD BE LOOKING AT THIS POST FDA APPROVAL - IF SO IT MAY BE THAT AGL WOULD LIKE THE SP TO DROP A BIT MORE (even as far as 50%).
Cannot see any reason why the SP will rise during this time - unless the shares are consolidated and we actually get listed on NASDAQ?
It's all very well the medical profession being aware of parsortix ((one exception being my surgery) but it is the outside world that invests. ANGLE could do with a good PR department which they appear to be sadly lacking at the moment.
DELETE YEAR INSERT JUNE